Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline

Eli Lilly and Company is making a cash acquisition move aimed at deepening its autoimmune drug portfolio. The Indianapolis-based drugmaker agreed to buy privately held Merida Biosciences for up to $2.875 billion, according to a report citing the deal terms.

Under the proposed agreement, Lilly would pay an upfront amount in cash and could make additional milestone-based payments as development or regulatory milestones are met. The total consideration is described as capped at $2.875 billion, placing the transaction at roughly $2.88 billion based on the round figure highlighted in the coverage.

The announced price underscores how valuable late-stage discovery and early clinical assets can be in the life sciences sector, particularly in areas where patients have limited treatment options and where new biologics and targeted medicines remain in high demand. For Lilly, the purchase is positioned as an “autoimmune bet,” reflecting the therapeutic area associated with Merida Biosciences’ work.

Lilly has repeatedly tied its growth strategy to expanding its pipeline through internal development and selective partnering and acquisitions, and this agreement fits that broader approach. Autoimmune diseases represent a large market opportunity, but they also carry significant scientific and commercial risk because outcomes depend on whether an intervention proves safe and effective in humans and can be translated into durable clinical benefit.

What the deal coverage does not provide is the specific product or program Lilly is acquiring, including the molecular target, the stage of development, trial designs, or expected regulatory timing. That missing detail matters because milestone payments typically track development progress, and the identity of the underlying asset often indicates how much of the price is tied to scientific risk versus later-stage execution.

The reporting also leaves open questions about the structure of the milestone framework. While it states that some portion of the consideration is milestone-based, it does not disclose the individual triggers, the potential payment schedule, or how likely each milestone is to be achieved. Without that, investors and analysts can only assess the deal as a high-level allocation of capital rather than a fully quantified bet on specific endpoints.

A separate uncertainty is the closing timeline and the conditions that must be satisfied before the transaction is completed. Acquisitions in drug development frequently depend on customary regulatory and closing conditions, but the coverage summarized here does not provide the specific timing or whether any approvals have already been secured.

For Lilly’s next steps, the key items to watch are the publication of deal documentation, including the precise terms of the upfront and milestone payments, and any additional disclosures about Merida’s science, clinical status, and near-term development plans. That information will determine whether the transaction is best viewed as a low- to moderate-risk add-on or as a more speculative bet on early research translating into approved therapies.